Analysts rave over Biogen MS pill on second Phase III successPharma TimesDr O'Neill also highlighted the promise being shown by PEG-Avonex and Abbott-partnered daclizumab, both of which are expected to report Phase III data in 2013. The company is …
Biogen Idec, Abbott present efficacy data of DAC HYP in RRMS treatmentPharmaceutical Business ReviewBiogen Idec and Abbott have reported the additional results from the Select Phase 2b trial, which assessed the investigational compound daclizumab high-…
Proactive Investors USA & CanadaBiogen Idec (BIIB) Shares Given New $127.00 Price Target by Oppenheimer (OPY …LocalizedUSAIt includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and…
Chronic Fatigue Syndrome — A Treatable Autoimmune DiseaseHuffington Post (blog)They decided to treat 30 people with CFS, mainly young (average age 37.3 for those treated and 31.5 years for placebo) and female (80 percent) with rituximab, a potent anti…
Kidney Graft Loss Due to BK Virus Need Not Prevent RetransplantationRenal and Urology NewsHowever, replacing alemtuzumab with basiliximab may be necessary to achieve optimal outcomes in retransplanted patients, according to data presented at the Infect…
Abbott Labs: Genes Aren't The Only Thing That Can Effectively Be SplicedSeeking AlphaOne such drug is Daclizumab. Abbott just reported positive Phase 2b trial results for the drug in treating multiple sclerosis. Patients enrolled in the study saw u…
Driven by the Launch and Uptake of Human Genome Sciences/GlaxoSmithKline's …MarketWatch (press release)The continued uptake of the premium-priced B-cell modulator rituximab will help to drive SLE market growth. Rituximab will achieve sales of nea…
Treatment for Chronic Fatigue Syndrome developed from cancer drug RituximabActive QuoteCancer drug Rituximab has been shown to successfully treat the symptoms of chronic fatigue syndrome (CFS), supporting the theory that CFS is an autoimmune disease. A…
Abbott, Biogen report MS drug reduced relapse rateBusinessWeekBiogen Idec and Abbott Laboratories said Sunday a mid-stage study of their multiple sclerosis medicine daclizumab showed that the experimental drug worked better than placebo at preventing r…
Quick Sequential Regimen Shows Promise As Preparative Therapy Prior To Stem …The MDS BeaconIn addition, most of the 30 patients in the study received anti-thymocyte globulin (ATG) for several days between induction and conditioning therapy to help pr…